SCHEMBL2045705

SCHEMBL2045705

CCOC(C)OP(=O)(O)O

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.50
SMPD1 P17405 3/20 0.41
MEN1 O00255 1/20 0.38
CYP1A2 P05177 1/20 0.38
KMT2A Q03164 1/20 0.38
FDPS P14324 2/20 0.34
METAP1 P53582 1/20 0.34
THRB P10828 1/20 0.33
PTPN1 P18031 1/20 0.33
PPARD Q03181 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.31
LPAR1 Q92633 2/20 0.31
LPAR3 Q9UBY5 2/20 0.31
LPAR2 Q9HBW0 1/20 0.31
ALDH1A1 P00352 1/20 0.31
TDP1 Q9NUW8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL28981357 0.96 LMNA (0.46) LMNASMPD1MEN1CYP1A2KMT2A
SCHEMBL28101537 0.89 LMNA (0.44) LMNASMPD1MEN1CYP1A2KMT2A
SCHEMBL2518475 0.86 LMNA (0.50) LMNASMPD1MEN1CYP1A2KMT2A
SCHEMBL28767714 0.84 LPAR3 (0.38) LMNASMPD1MEN1CYP1A2KMT2A
Phosphoric Acid SCHEMBL368038 0.82 LMNA (0.67) LMNAMEN1CYP1A2KMT2AFDPS
SCHEMBL2046370 0.82 SMPD1 (0.42) SMPD1FDPSMETAP1PTPN1LPAR1
SCHEMBL11591189 0.80 LMNA (0.44) LMNAMEN1CYP1A2KMT2AFDPS
SCHEMBL2045703 0.80 LMNA (0.55) LMNAMEN1CYP1A2KMT2ATHRB
Itaconate SCHEMBL9419185 0.80 ALOX15 (0.40) LMNA
SCHEMBL10447789 0.79 SMPD1 (0.39) SMPD1FDPSMETAP1PTPN1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024259923-A1 INTERPENETRATING NETWORK TYPE PVDC EMULSION AND PREPARATION METHOD THEREFOR 浙江衢州巨塑化工有限公司 2024-12-26 WO claimed
EP-4034094-B1 PHOSPHODIESTERASE INHIBITORS AND USE ZENSHINE PHARMACEUTICALS NANJING GROUP CO LTD (CN) 2026-04-15 EP disclosed
US-20260091148-A1 DIAGNOSTIC PET IMAGING OF CARDIAC AMYLOIDOSIS Higuchi, Takahiro (DE) 2026-04-02 US disclosed
US-12590084-B2 Oxadiazole HDAC6 inhibitors and uses thereof EIKONIZO THERAPEUTICS, INC. (US) 2026-03-31 US disclosed
US-20260078119-A1 DEGRADER COMPOUNDS AND USES THEREOF BRISTOL MYERS SQUIBB CO (US) 2026-03-19 US disclosed
US-20260055090-A1 OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF EIKONIZO THERAPEUTICS, INC. (US) 2026-02-26 US disclosed
EP-4698530-A1 NK3 MODULATORS AND USES THEREOF Kallyope, Inc. (US) 2026-02-25 EP disclosed
US-12544448-B2 C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors Revolution Medicines, Inc. (US) 2026-02-10 US disclosed
US-20260035361-A1 COMPOUNDS FOR MODULATING HUR (ELAVL1) SHANGHAI DEGRON BIOMEDICAL TECH CO LTD (CN) 2026-02-05 US disclosed
US-20260015350-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS MIRATI THERAPEUTICS INC (US) 2026-01-15 US disclosed
EP-2337805-A1 POLYMERIZABLE LIQUID COMPOSITION AND PROCESS FOR THE PRODUCTION OF ORGANIC GLASS STARTING FROM POLYMERIZABLE LIQUID COMPOSITIONS OF THE POLYURETHANE TYPE ACOMON AG (CH) 2011-06-29 EP disclosed
WO-2010043392-A1 POLYMERIZABLE LIQUID COMPOSITION AND PROCESS FOR THE PRODUCTION OF ORGANIC GLASS STARTING FROM POLYMERIZABLE LIQUID COMPOSITIONS OF THE POLYURETHANE TYPE ACOMON AG (CH) 2010-04-22 WO disclosed
US-7585907-B2 Inorganic powder-containing resin composition, a film-forming material layer, a transfer sheet, method of producing a substrate having a dielectric layer formed thereon, and a substrate having a dielectric layer formed thereon NITTO DENKO CORPORATION (JP) 2009-09-08 US disclosed
US-20060199883-A1 Inorganic powder-containing resin composition, film-forming material layer, transfer sheet, method for producing substrate with dielectric layer, and substrate with dielectric layer NITTO DENKO CORPORATION (JP) 2006-09-07 US disclosed
EP-1666526-A1 INORGANIC POWDER-CONTAINING RESIN COMPOSITION, FILM-FORMING MATERIAL LAYER, TRANSFER SHEET, METHOD FOR PRODUCING SUBSTRATE WITH DIELECTRIC LAYER, AND SUBSTRATE WITH DIELECTRIC LAYER NITTO DENKO CORPORATION (JP) 2006-06-07 EP disclosed
US-20050142413-A1 Separator for fuel cell, method for producing the same, and fuel cell using the same SANSHO KAKOU CO., LTD. (JP) 2005-06-30 US disclosed
EP-0537426-B1 A germicidal and fungicidal agent and a germicidal and fungicidal method NICCA CHEMICAL CO (JP) 1995-12-27 EP disclosed
US-5362910-A Germicidal and fungicidal agent and a germicidal and fungicidal method NICCA CHEMICAL CO., LTD. (JP) 1994-11-08 US disclosed
EP-0537426-A1 A germicidal and fungicidal agent and a germicidal and fungicidal method NICCA CHEMICAL CO., LTD. (JP) 1993-04-21 EP disclosed
US-4297468-A CONTAINING UNITS DERIVED FROM AN UNSATURATED CARBOXYLIC ACID, AND ONE OTHER UNSATURATED COMPOUND CHEMISCHE FABRIK STOCKHAUSEN & CIE (DE) 1981-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260078119-A1 DEGRADER COMPOUNDS AND USES THEREOF CTTN, SRC, PTK2 LMNA 2215/4885SMPD1 4523/4885MEN1 2994/4885
US-12590084-B2 Oxadiazole HDAC6 inhibitors and uses thereof HDAC6, HDAC1, HDAC9 LMNA 3231/4885SMPD1 3846/4885MEN1 4699/4885
US-20260055090-A1 OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF HDAC6, HDAC1, CTTN LMNA 4412/4885SMPD1 4724/4885MEN1 3173/4885
US-20260091148-A1 DIAGNOSTIC PET IMAGING OF CARDIAC AMYLOIDOSIS TNNC1, TNNT2, TNNI3 LMNA 400/4885SMPD1 409/4885MEN1 965/4885
US-20260015350-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS KRAS, NRAS, HRAS LMNA 2151/4885SMPD1 2842/4885MEN1 304/4885
US-20260035361-A1 COMPOUNDS FOR MODULATING HUR (ELAVL1) ELAVL1, ELAVL3, HNRNPL LMNA 1137/4885SMPD1 3044/4885MEN1 1990/4885
US-12544448-B2 C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors RICTOR, MTOR, MLST8 LMNA 2304/4885SMPD1 2200/4885MEN1 380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.